Adagene inc ADAG.US 總覽分析

美股醫療保健
(ADAG 無簡報檔)

ADAG 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低,若以價值投資為目標且有長期投資部位,需要嚴格執行自己的出場計畫來減持部位

ADAG 近期報酬表現

6.25%

Adagene inc

4.57%

同產業平均

3.26%

S&P500

與 ADAG 同產業的標的表現

  • CRBP Corbus pharmaceuticals holdings inc
    價值 2 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分
    查看更多

ADAG 公司資訊

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company's main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG 股價